Eli Lilly and Company (NYSE: LLY) revealed today that FDA has awarded emergency use authorization to its arthritis drug Baricitinib in combination with Gilead Sciences’ remdesivir for the treatment of COVID-19 patients in the hospital. FDA has allowed the emergency use for the treatment of novel coronavirus for which there is no alternative remedy is available.

The consent to use Baricitinib is only for a temporary basis. It has been uncovered that the use of Baricitinib in combination with remdesivir has diminished the cure time to 29 days after getting treatment. Eli Lilly is endeavoring to deliver a new remedy for the disease which has affected millions of people around the world. This arthritis drug has not got an endorsement in the US to treat COVID-19 patients by the FDA.